Expected Hepatitis C complications in patients treated with DCV/ASV versus PR.

Constanza L. Vargas (823194)
Manuel A. Espinoza (823195)
Andrés Giglio (823196)
Alejandro Soza (823197)

Publication date

November 2015

DOI

10.1371/journal.pone.0141660.t004

Abstract

<p>HCV: Hepatitis C Virus, PR: Peginterferon plus Ribavirin, PIs: Protease Inhibitors, DCV/ASV: Daclatasvir plus Asunaprevir, F4: cirrhosis, DC: Decompensated cirrhosis, HCC: hepatocellular carcinoma, HT: liver transplant, BCI: Bayesian credibility interval.</p><p>Expected Hepatitis C complications in patients treated with DCV/ASV versus PR.</p